Case Study: Clovis Oncology
Read our case study on how Clovis Oncology leveraged our unique integrated programs to efficiently meet their program goals.
Clovis Oncology was a US-based biopharmaceutical company that focused on acquiring, developing, and commercializing cancer treatments for global markets. Their development programs were targeted at specific subsets of cancer, and combined personalized medicine with companion diagnostics, aiming to create therapeutics that were directed at the patients most likely to benefit from them.
They chose to work with Quotient Sciences' to take advantage of our Translational Pharmaceutics® platform for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer. Performed on healthy volunteers, this flexible, data-driven Phase I development study enabled the rapid development of an optimized salt formulation.
Request a copy of our case study with Clovis Oncology today to find out more about the real-world benefits of our integrated approach.